Daily Stormer The Most Censored Publication in History
First report of an association of a GLP-1 drug (semaglutide) and risk of NAION, a form of optic neuropathy (2nd most common cause of blindness after glaucoma) in a matched cohort of ~17,000 individualshttps://t.co/GyQ8omkCt4 @JAMAOphth pic.twitter.com/uHa381EpII
— Eric Topol (@EricTopol) July 3, 2024
As we’ve always said: nothing is free.
When you go to a witch and have her do something for you, she demands you sacrifice something.
When you take magic weight loss pills because you are literally incapable of regulating what goes into your mouth, you go blind.
People who have been prescribed a weight-loss injection could be at a higher risk of developing an eye condition which can lead to blindness, a study has found.
The study found that people with diabetes who were prescribed semaglutide, most commonly known under the brand names Wegovy and Ozempic, were more than four times more likely to be diagnosed with an eye condition known as non-arteritic anterior ischemic optic neuropathy (naion).
Naion is a disorder in which the arteries which supply blood to the optic nerve in the eye become blocked. The condition can lead to loss of eyesight due to the optic nerve being deprived of oxygen and subsequently damaged. There is no known treatment for the condition, which affects 10 out of 100,000 people in the general population.
The research, published in the journal JAMA Ophthalmology and conducted by researchers at Harvard University, looked at data from 16,827 patients at the Mass Eye and Ear Harvard teaching hospital, who received treatment over a six-year period.
Of the patients included within the study, 710 had type 2 diabetes, with 194 of those patients having been prescribed semaglutide.
Included in the study were 975 patients who were overweight or living with obesity, with 361 of these having been prescribed semaglutide.
Of the people included in the study with type 2 diabetes, 17 naion events occurred in patients who were prescribed semaglutide, compared with six who were on other diabetes drugs.
Over three years, 8.9% of these people on semaglutide had naion compared with 1.8% on the other drugs, the researchers found.
The study also found that people who were overweight or living with obesity who were prescribed semaglutide were more than seven times more likely to develop the condition than those on other types of weight-loss medicine.
Everyone who knows anything about anything was saying “it will be interesting to see what kinds of disastrous side effects these weight loss drugs cause.”
Well, now we’re starting to have that question answered.
Related: “Weight Loss Drug” Causing Stomach Paralysis (Drugs to Change Behavior are an Insane Concept)
Ahem.
Semaglutide INCREASES diabetic retinopathy complications.
INCREASES. BLINDNESS.
But this result is inconsistent with beliefs of the expert committee members. So…#3DCME@Drug_Evidence@CaitO_PharmD pic.twitter.com/CiWvhBKQra
— Dr. Rita McCracken, MD, PhD (she/her) (@DrRitaMc) May 27, 2018
